Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs
Watch the vodcast on emerging biomarkers in thyroid and non-small cell lung cancers
About the expert
Prof. Andrew Beggs
Prof. Beggs is a Professor of Cancer Genetics & Surgery in the Institute of Cancer and Genomic Sciences, University of Birmingham and Deputy Director of the Birmingham Experimental Cancer Medicine Centre.
Grant funding: AstraZeneca Plc, Incyte Inc, MSD, Moderna, Oxford Nanopore, Thermo Scientific, Illumina, BioNano, Innova Medical
Consultancy: Oxford Nanopore, Check4Cancer, Kiffik Biomedical, 2CureX Ag
In kind support: MGITech, Illumina, Congenica, Qiagen
Salary support: MRC Senior Clinical Fellowship
This content is intended only for healthcare providers and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company.
Any information provided and opinions expressed do not necessarily reflect the views of Springer Healthcare Limited (part of the Springer Nature Group) or the Medicine Matters Editorial Board. Springer Healthcare Limited and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.
Attention: This content is intended for healthcare professionals only
In order to proceed please confirm whether you are a healthcare professional.